pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-382 |
Genomic Coordinates | chr14: 101054306 - 101054381 |
Synonyms | MIRN382, hsa-mir-382, MIR382 |
Description | Homo sapiens miR-382 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-382-3p | ||||||||||||||||||||||||
Sequence | 47| AAUCAUUCACGGACAACACUU |67 | ||||||||||||||||||||||||
Evidence | Not_experimental | ||||||||||||||||||||||||
Experiments | |||||||||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SPATA13 | ||||||||||||||||||||
Synonyms | ARHGEF29, ASEF2 | ||||||||||||||||||||
Description | spermatogenesis associated 13 | ||||||||||||||||||||
Transcript | NM_001166271 | ||||||||||||||||||||
Other Transcripts | NM_153023 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SPATA13 | |||||||||||||||||||||
3'UTR of SPATA13 (miRNA target sites are highlighted) |
>SPATA13|NM_001166271|3'UTR 1 AAACAGGAGGCTGTGCTTCCATGGAGCTGGGTGTCAAGAGAAGAACTGTCTTTGTTTCTTGTGTGCTTCAATCCAGGGAA 81 AGTTTCTTGGACCCAGTGATAAAAACTTCCTTTTAGGGATCAATGAAGGAGAGAAGGTCTTGGAATCACCTTCAGTCTTT 161 GGAGACCCAGCTGCCTTTGTGGAAGGGAGGAGACGGTCATGACACAAAGCTTTATCCTACACAGAAACACCCGTGACCCA 241 CTATGAGATGGCCCAGATGTGGGACCCGGTACCATGCTCTAAAGCGAGTGATTAGGCAGCAGCTGAAGCCACCCCTGCTG 321 ATGATGAGCAAGTGCCTGCTGCAGGTCCAAACACAGCATCCAGGGCTTTGCAGTTCCTAAGGAGTGATGAGGTTAGAGGA 401 TCACTTCTGCATTTGATTTTCAAGGATGCCGTCAAGACGGGGTTGACACAATGCTGCACGTGTCTGGTCACACTTAGAAA 481 TTGAGCTCTTACTCTCTTCTGTAATACTGGGGGACCTACAGCTGCCGTGGGGCTGACCACGGTGTTCCCTGGCATCGTCT 561 GTGTCCACACAGATGCTAACTGGTAGTGCAAATGTCATCCTGCAAGGTTCCTCTTCCTGCAAGCAAAGTGGAGAGAAAGA 641 AGATGCATCTGTCACCTTCATCAGGGTCCTCAGTGCAGAGCAACTTACGCATCCTCAAGAATCCACTGCTTTTCAGGCAA 721 GGAGGGAGAAATCCTGCTGCACACTGGCTTTGTCCCGGAGTCGGATTCCCTCCTGCCTGCACGCCTTCAGTAACTCCGAG 801 CAGAAATCACATCTTGCCCACATGCTGTAACCTAAGAAACTGCTATGCAAGGCTGGGTGCTGTGGCTCATGCCTGTAATC 881 CCAGCACTTTGGGAGGCCAAGGCAGGTGGATCACCTGAGGTCAGGAGTTCGAGACAAGCGTGGCCAATATGGCAAAGCCC 961 AGTCTCTACTAATAATACAAAAATTAGCTGGGCATGGTGGCGCATGCCTGTAATCCCAGCTACTGGGAAGGCTGAGGTAG 1041 GAGAATCTTTTGAATCTGGGAAGCGGAGGTTGCAGTGAGCTGAGATCGCACCACTGCACTCCAGCCTGGGAGATACAGCG 1121 AGACTGTCTCCAAAAACAAAAACAAAAACAAAAAACATTCAAACAACTGTTTGCAATATAAAAAGCTCATTTACTGTAAT 1201 ATTTATGATACAGTGAATATGAAAATGCACTGGTCAGAAGGCACTCTCAAAGAGCCGCACTGCTCCTGACATCGTCCTTA 1281 GCAATGAAGTCACAAAGACAGCCAAAGCAGTCCTGCTTCTTGGAAATCAGAAGCTGCCTTTATCACATATAAAGCCAAAC 1361 AGGGCATAACCATGTCACGTGAGCATGTCATCAGGCTTCTGAGGACTTGTTCTTTATAAAAAAAGACCTTCACAAAATAT 1441 CTTGGCTTAGAGATAGCAGTCTTTATTAACAAAGGCCACCTAGGCTGACACCTGCAGATAATCATCTCCTTTTCTTTGTC 1521 TATGTTGTACATTTTCATGATATAACTTTTAACTATGTCTAGAGAAGGCAGGCTCTGCAAGAGAGGTGCCCTTTCAACCC 1601 GCTCAGTGCCCTGGACAGGAGATGCTGTGTTAAACTGTTAATGGATATCTATATGAGAAGCTCATTTTTGTATGCTATCC 1681 CTGCAGTTTTTTTTTTTCTAACAGGCCCATGTTTGAGAATAAACAAGTCTGTGATGTCAGAGACAAAGGTGTATTCTTCA 1761 GTCTGCAGGTGTGTGGCACCTCCCTTCTCCCCTGCAGCCCCCCACATCCAGAGCCGTTCCTGAGAGTGACATCATGCATC 1841 AAGAAAACATAACCTTGGTCCTCAGGTGAACCCTTGGAACATTCTGTGACCGCCTGATGTCCATTCTGAGCCACCTTGGC 1921 ACACATGCTTACAGGCAGCACTGCTAAGGGTTCAGGTGCCCCATGGCTGACAGCCCGAGTTGCTTCTGTGGACCATCATG 2001 CCGCTCGGCACGTCCTGAGACAGAAGTTGCTGCAGGAAGGAGCTTCTGGAGAGGTCCTGTGGCATGTGTGGGGGTGTGTG 2081 TGTGTATGTTTCCTTCTTGAACAGACATTCCAACTTTAGATGTGTTTATAGAACTGACCTTTTTACTAACAAAATACAAT 2161 GATATATGTTGGAAACTACTTAATATGCTTTTCCTGCACACCTTAGCAATAACTGTAGGGGTCTCTGCTAGAGTTGTTTG 2241 TATGTACAGCAATTTTGAACAAATTGTTTTAAATGTAATATAAGAGAATTAGTTTAAGGAAGTAAAGAGAATCATTTGCT 2321 TGTGTTACATTTTCAGTGAGGATTCAGTTTAAGAGTCATTCTTAGGACTTCCATTTCCTAATATTTATTCATGGGTAATG 2401 AAGAAATGGTTTGCATTTTGTGGCCAGTCCTAATTTATTTTCCAGCTGAGCCCTAACTTCCGGCTCCCACCTACCTCCAC 2481 GGACTTCCTAACAGAGACTTATGAATACCAGGATGTGTTTTTGTTAAGTCAGGTTCAATTCGTTGCCCCTGTCAGTTTTA 2561 TAGAGTGTGAGGGTCACTCCATTAAAGATCTCTCCTGGGTGGATCCTACTTGGATGTTCAGGTGATTTTGAAAACTGCTA 2641 ACATTTTTAAAAGGCTAGAACATCCTTTGACTTCTTGAAAATCTGCATGTCTGGCTTGGGTTTTATTACCACATGCCTGA 2721 GTTCTTCAAGAATGGAAGGCTCAAGTATTCTCATCTTCCATTTGCCAAACTTCCTTCCTGATTTGAGTCACGTGTTCCAC 2801 TTGGAAAGAAAGGGAACAGAGAGCCTCCTCCATGGACAGTGTATGAATTTCATTGGGAATCTTGCTCTCTCCCGCCTCTA 2881 TGCCTTTCTCTCTTTTTAACCTTACTTTACATAATATTATAGATGGGCCAAGAAAAGAAAAGATGACATAACATTTTGAT 2961 GAATTTCACCTATTCCATTCTTCACGTTTCAGAATTGGTCGACTTTGTTAGAAGATAATTGAAGTAGCCTTGGGTCAAAA 3041 GCAACCTTTTCAATTGTGATCATACCTAAAACATATAAAAACCCTGCCGTAGATTAAAAGCAATTATAAAATCATAAAAT 3121 TGAATGTTTGCAGAATCCTGGAGCAGTAGATTTCTTTGTCTTTGGCCTGCGGACTAGAAAGAGGGCAGCAGTAGTATGCT 3201 GGAGCTTCCCTGGGATACCAGCCACATGGTTTCTTTTCATTAGATCTGATTTTTGTTTCCCACTGTAGATCTGATTTTGT 3281 AGTTGAAAACATTTCACCACCATCAAACACTATTTCTGAATATTGTGCCTTTTTATACCTAGCCTAGATGAAAACCGATG 3361 CCATTCTTATTCAGAAAATCCCCCCATCCTACATGACTGTTATCTAGACATAAAGCAAAGTGCATTTAATTCAAAATTTG 3441 GTTCACAATATAAGTATTTTGTAAAAGCCAGCTGAACCAGCATTTTATCAGGTGGAAATCTCTGCAAGCCAAATTGCTGA 3521 TACTCCTTCATGCAGATCAACTTGGTGTCCCAGTCAGAATAGAACAGCATAATTACCTGGAGTTAGGGGGAGTATTTCTG 3601 CACTATTACTTGTCAGGGAGAGAAGAAACTTAGAATTGTCCCTCAAAGGAGTGTCAAGAAGTATGAATAAATGTCCTTTC 3681 ACCAGCTCACAGGCCAGAAATGGAGGACCCAAGTCAACTAGGTGAAACTACTAGCAGACCCAGCTTTCCCATAATAACCT 3761 AATCTGCAAATTGTTCTATTAAAGTCTCATTGTTTTCAGGATGCAATGAAAGTGGATTTCAAAAGGCTTTGGAAAAATAA 3841 GTGGAACATGACTGATCTTGAAAAAAAAAGCAAAAGCTTAAATATTTGATACAAGTTTACTTAGCTACAACATACTTTAC 3921 ATTGTTGCCTTTAGTTATCTCACAGGCACTGACATTTTATATTTAGAAAATACTTTTAATCTTTCTAATCTTTTTTTGTA 4001 AATATTAGTGTCCATTCTGTATGACTCGCTAACCTACTTTGCAAGGCTTTGGGCAACATTTTAGCTCATTAACTTCAAGA 4081 TGATGTGTCATCTGTATAGGTCAAAGAATGGGACTTCTGAACTGAGGAATTTGCTGTTGACAGCCAAAGTATAGTGTACA 4161 AGATTGATGTAACTTGATATGTATTTTTGTTGAAGTTTTTTGTAAAAAAAAATTATTTACAATGTTATTTGAATGATTTT 4241 TTTAAATGCTGTGAATCTATATTTGTTGTTTTGTATATTAAAATTCATTTGCCAAACTCGT Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | MCF7 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000382108.3 | 3UTR | AUUUUUUUAAAUGCUGUGAAUCUAUAUUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000382108.3 | 3UTR | AUUUUUUUAAAUGCUGUGAAUCUAUAUUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
79 hsa-miR-382-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT062248 | HP1BP3 | heterochromatin protein 1 binding protein 3 | 1 | 1 | ||||||||
MIRT068067 | SPATA13 | spermatogenesis associated 13 | 2 | 4 | ||||||||
MIRT142409 | TNRC6A | trinucleotide repeat containing 6A | 2 | 6 | ||||||||
MIRT257487 | ABT1 | activator of basal transcription 1 | 2 | 6 | ||||||||
MIRT439244 | ZCRB1 | zinc finger CCHC-type and RNA binding motif containing 1 | 1 | 1 | ||||||||
MIRT439345 | UHMK1 | U2AF homology motif kinase 1 | 1 | 1 | ||||||||
MIRT439466 | TGFBR3 | transforming growth factor beta receptor 3 | 1 | 1 | ||||||||
MIRT439506 | SURF4 | surfeit 4 | 1 | 1 | ||||||||
MIRT439733 | RPS4X | ribosomal protein S4, X-linked | 1 | 1 | ||||||||
MIRT439888 | PRUNE2 | prune homolog 2 | 1 | 1 | ||||||||
MIRT439984 | PHLDB2 | pleckstrin homology like domain family B member 2 | 1 | 1 | ||||||||
MIRT440132 | NCOA3 | nuclear receptor coactivator 3 | 1 | 1 | ||||||||
MIRT440291 | MAP2 | microtubule associated protein 2 | 1 | 1 | ||||||||
MIRT440434 | IPPK | inositol-pentakisphosphate 2-kinase | 1 | 1 | ||||||||
MIRT440515 | HERC2 | HECT and RLD domain containing E3 ubiquitin protein ligase 2 | 1 | 1 | ||||||||
MIRT440723 | ENO2 | enolase 2 | 1 | 1 | ||||||||
MIRT440898 | CPEB4 | cytoplasmic polyadenylation element binding protein 4 | 1 | 1 | ||||||||
MIRT441013 | CAPN7 | calpain 7 | 1 | 1 | ||||||||
MIRT448953 | CDK19 | cyclin dependent kinase 19 | 2 | 2 | ||||||||
MIRT466663 | TAF1D | TATA-box binding protein associated factor, RNA polymerase I subunit D | 2 | 4 | ||||||||
MIRT471447 | PDIA5 | protein disulfide isomerase family A member 5 | 2 | 2 | ||||||||
MIRT496398 | ZSCAN16 | zinc finger and SCAN domain containing 16 | 2 | 2 | ||||||||
MIRT497519 | EXOC8 | exocyst complex component 8 | 2 | 2 | ||||||||
MIRT501782 | NRBF2 | nuclear receptor binding factor 2 | 2 | 6 | ||||||||
MIRT504199 | KIAA1586 | KIAA1586 | 2 | 4 | ||||||||
MIRT505076 | ZC3H12C | zinc finger CCCH-type containing 12C | 2 | 8 | ||||||||
MIRT509814 | SULT1B1 | sulfotransferase family 1B member 1 | 2 | 4 | ||||||||
MIRT518477 | C8orf37 | chromosome 8 open reading frame 37 | 2 | 4 | ||||||||
MIRT520345 | UBN2 | ubinuclein 2 | 2 | 10 | ||||||||
MIRT527579 | BRD7 | bromodomain containing 7 | 2 | 4 | ||||||||
MIRT531742 | TXK | TXK tyrosine kinase | 2 | 2 | ||||||||
MIRT533354 | UBE2W | ubiquitin conjugating enzyme E2 W | 2 | 2 | ||||||||
MIRT535735 | MYO6 | myosin VI | 2 | 2 | ||||||||
MIRT537113 | GP5 | glycoprotein V platelet | 2 | 4 | ||||||||
MIRT542398 | TFCP2 | transcription factor CP2 | 2 | 8 | ||||||||
MIRT547560 | LRIG3 | leucine rich repeats and immunoglobulin like domains 3 | 2 | 4 | ||||||||
MIRT551649 | CCDC127 | coiled-coil domain containing 127 | 2 | 2 | ||||||||
MIRT554959 | RACGAP1 | Rac GTPase activating protein 1 | 2 | 2 | ||||||||
MIRT555202 | PRRX1 | paired related homeobox 1 | 2 | 2 | ||||||||
MIRT555768 | PCTP | phosphatidylcholine transfer protein | 2 | 2 | ||||||||
MIRT558971 | CALM1 | calmodulin 1 | 2 | 2 | ||||||||
MIRT559668 | AGO3 | argonaute 3, RISC catalytic component | 2 | 2 | ||||||||
MIRT566688 | MYLIP | myosin regulatory light chain interacting protein | 2 | 2 | ||||||||
MIRT568588 | AGO2 | argonaute 2, RISC catalytic component | 2 | 2 | ||||||||
MIRT568643 | ACTB | actin beta | 2 | 2 | ||||||||
MIRT568775 | LY6K | lymphocyte antigen 6 family member K | 2 | 2 | ||||||||
MIRT573442 | APOPT1 | apoptogenic 1, mitochondrial | 2 | 2 | ||||||||
MIRT611400 | ATP9A | ATPase phospholipid transporting 9A (putative) | 2 | 2 | ||||||||
MIRT623867 | GABRB2 | gamma-aminobutyric acid type A receptor beta2 subunit | 2 | 2 | ||||||||
MIRT627266 | XKR4 | XK related 4 | 2 | 2 | ||||||||
MIRT631666 | NDUFV3 | NADH:ubiquinone oxidoreductase subunit V3 | 2 | 2 | ||||||||
MIRT635085 | LIMS3 | LIM zinc finger domain containing 3 | 2 | 2 | ||||||||
MIRT635154 | LIMS3L | LIM zinc finger domain containing 4 | 2 | 2 | ||||||||
MIRT639057 | FPR1 | formyl peptide receptor 1 | 2 | 2 | ||||||||
MIRT642763 | SDHAF2 | succinate dehydrogenase complex assembly factor 2 | 2 | 2 | ||||||||
MIRT643385 | CLMP | CXADR like membrane protein | 2 | 2 | ||||||||
MIRT647390 | ZNF616 | zinc finger protein 616 | 2 | 2 | ||||||||
MIRT647435 | ZKSCAN2 | zinc finger with KRAB and SCAN domains 2 | 2 | 2 | ||||||||
MIRT649067 | HSD17B12 | hydroxysteroid 17-beta dehydrogenase 12 | 2 | 2 | ||||||||
MIRT653017 | STX7 | syntaxin 7 | 2 | 2 | ||||||||
MIRT654321 | RBM47 | RNA binding motif protein 47 | 2 | 2 | ||||||||
MIRT654773 | PRKAA2 | protein kinase AMP-activated catalytic subunit alpha 2 | 2 | 2 | ||||||||
MIRT657853 | GJD3 | gap junction protein delta 3 | 2 | 2 | ||||||||
MIRT662944 | MEAF6 | MYST/Esa1 associated factor 6 | 2 | 2 | ||||||||
MIRT698739 | STX12 | syntaxin 12 | 2 | 2 | ||||||||
MIRT699384 | SLC30A6 | solute carrier family 30 member 6 | 2 | 2 | ||||||||
MIRT700215 | REL | REL proto-oncogene, NF-kB subunit | 2 | 2 | ||||||||
MIRT702626 | ITGBL1 | integrin subunit beta like 1 | 2 | 2 | ||||||||
MIRT709824 | STPG1 | sperm tail PG-rich repeat containing 1 | 2 | 2 | ||||||||
MIRT711075 | NLGN2 | neuroligin 2 | 2 | 2 | ||||||||
MIRT712835 | GJD2 | gap junction protein delta 2 | 2 | 2 | ||||||||
MIRT713307 | TYRP1 | tyrosinase related protein 1 | 2 | 2 | ||||||||
MIRT713726 | CD244 | CD244 molecule | 2 | 2 | ||||||||
MIRT715558 | EPT1 | selenoprotein I | 2 | 2 | ||||||||
MIRT717285 | TRAF1 | TNF receptor associated factor 1 | 2 | 2 | ||||||||
MIRT724543 | RSL24D1 | ribosomal L24 domain containing 1 | 2 | 2 | ||||||||
MIRT735691 | SMAD2 | SMAD family member 2 | 2 | 0 | ||||||||
MIRT755903 | SLIT2 | slit guidance ligand 2 | 3 | 1 | ||||||||
MIRT756166 | SAE1 | SUMO1 activating enzyme subunit 1 | 5 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|